Effects of glimepiride and glibenclamide on carotid atherosclerosis in type 2 diabetic patients.
We performed a 3-year observation study of type 2 diabetic patients treated with glibenclamide or glimepiride and found that the annual progression of the maximum carotid intima-media thickness was significantly attenuated in the subjects treated with glimepiride (n=20) as compared with those treated with glibenclamide (n=20) (-0.044±0.171 mm/year vs. 0.077±0.203 mm/year, p=0.0474).
Department of Metabolic Medicine, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita City, Osaka 565-0871, Japan. katakami@medone.med.osaka-u.ac.jp
Naoto
N
Katakami
Hideaki
H
Kaneto
Munehide
M
Matsuhisa
Iichiro
I
Shimomura
Yoshimitsu
Y
Yamasaki
D000368:Aged; D002340:Carotid Artery Diseases / Q000188:drug therapy* / Q000503:physiopathology*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology*; D005260:Female; D005905:Glyburide / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*; D016896:Treatment Outcome
D007004:Hypoglycemic Agents; D013453:Sulfonylurea Compounds; C057619:glimepiride; D005905:Glyburide